In less than a decade, the resources available to treat light chain (AL) amyloidosis have increased impressively.
Giovanni Palladini, MD, PhD
Advertisement
Articles by Giovanni Palladini, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
TOP Trial: Chemo-Osimertinib in TP53-Mutant EGFR-Mutated NSCLC
2
FLAURA2: Osimertinib Plus Chemo in EGFR-Mutant NSCLC
3
Access to Care and Drug Prices: Recent Department of Health and Human Services Guidance
4
Sequencing CELMoDs With BsAbs and CAR T as a 'Sandwich Strategy' in Multiple Myeloma
5